Ischemic stroke prevention: an update on antiplatelet therapy

Area of Science:

• Neurology
• Pharmacology

Background:

• Stroke is a leading cause of death and disability globally.
• Antiplatelet therapy is the primary treatment for preventing recurrent atherothrombotic strokes.
• Recent advancements in antiplatelet agents necessitate updated treatment guidelines.

Purpose of the Study:

• To review individual antiplatelet agents.
• To summarize current guidelines for antiplatelet selection and use in stroke patients.
• To provide an update on antiplatelet therapy for transient ischemic attack and noncardiogenic ischemic stroke.

Main Methods:

• Review of mechanisms of action for antiplatelet agents.
• Analysis of demonstrated efficacy of antiplatelet therapies.
• Evaluation of adverse effect profiles.
• Summary of current consensus recommendations for antiplatelet use.

Main Results:

• Aspirin, ticlopidine, clopidogrel, and aspirin/extended-release dipyridamole are discussed.
• Efficacy and safety profiles vary among agents.
• Guidelines have evolved with new drug developments.

Conclusions:

• Antiplatelet agents are essential in managing patients at risk of recurrent stroke.
• Current guidelines emphasize individualized selection based on efficacy, safety, and patient factors.
• The combination of aspirin and extended-release dipyridamole offers an alternative therapeutic strategy.